Home › Atherosclerosis › South Carolina
Atherosclerosis clinical trials in South Carolina
6 studies for Atherosclerosis are looking for participants at sites in South Carolina.
Cities in South Carolina
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Accellacare Charleston, Mt. Pleasant
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Oct 5, 2026 · NCT07037433A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Monroe Biomedical Research - Charleston, North Charleston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07783802Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- M3 Wake Research - Charleston, Charleston
- Medical University of South Carolina, Charleston
- Walker Family Care, Little River
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Columbia Nephrology, Columbia
- CN Clinical Research LLC, Greenville
- Dialysis Clinic, Inc., Spartanburg
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Charleston
- Research Site, Fort Mill
- Research Site, Mauldin
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC, Columbia
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT02915198From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.